Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity

Fujiwara, Tsutomu; Ikeda, Masataka; Esumi, Kimio; Fujita, Tsuyoshi; Kono, Mitsuo; Tokushige, Hideki; Hatoyama, T; Maeda, Tetsuyuki; Asai, Tomohiro; Ogawa, Takahiro; Katsumata, Takashi; Sasaki, Shimaru; Suzuki, Eiji; Suzuki, Masahiro; Hino, Fumitsugu; Fujita, Toshio; Zaima, H; Shimada, Masamitsu; Sugawara, Tamio; Tsuzuki, Yasuhiro; Hashimoto, Yuka; Hishigaki, Haretsugu; Horimoto, Shingo; Miyajima, Nobuyuki; Yamamoto, Takumi; Imagawa, Kenichi; Sesoko, Shogo; Fujisawa, Y

doi:10.1038/sj.tpj.6500435

Cited by 26 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study showed that the homozygous CC genotype of COX-1-50C>T was dominant in a Chinese population, and that no TT genotype was found. This is in agreement with other studies in Japanese and Chinese populations (Fujiwara et al, 2007;Li et al, 2007). Few COX-1-50C>T polymorphisms have been examined in Asian populations.…”

Section: Discussionsupporting

confidence: 92%

Interaction between ALOX5AP-SG13S114A/T and COX-2-765G/C increases susceptibility to cerebral infarction in a Chinese population

Zhou²,

J³

et al. 2013

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We made a case-control study to investigate a possible association between ALOX5AP-SG13S114A/T, COX-2-765G/C, and COX-1-50C/T polymorphisms with cerebral infarction in a Chinese population. A total of 411 cases with cerebral infarction were included; 411 controls matched for age, gender, and risk factors were also selected. The ALOX5AP-SG13S114A/T (rs10507391), COX-2-765G/C (rs20417), and COX-1-50C/T (rs3842787) polymorphisms were determined using PCR-RFLP. The generalized multifactor dimensionality reduction method was employed to detect gene-gene interactions. Based on single-gene analysis, there were no significant differences in the genotype and allele frequency distributions of ALOX5AP-SG13S114A/T, COX-2-765G/C, and COX-1-50C/T between the cerebral infarction group and controls. However, in those cases carrying ALOX5AP-SG13S114AA as well as COX-2-765CC, the risk of cerebral infarction increased significantly by 2.84 times (95%CI = 1.324-6.543). The single-gene ALOX5AP-SG13S114A/T, COX-2-765G/C, and COX-1-50C/T polymorphisms appear not to be associated with the development of cerebral infarction in Chinese populations. However, the interaction between ALOX5AP-

show abstract

Section: Discussionsupporting

confidence: 92%

Interaction between ALOX5AP-SG13S114A/T and COX-2-765G/C increases susceptibility to cerebral infarction in a Chinese population

Zhou²,

J³

et al. 2013

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…12 However, only a few studies have evaluated the antiplatelet effect of aspirin in Japanese patients. 13, 14 Moreover, the long-term change in the antiplatelet effect of aspirin has not been evaluated in Japanese patients. In the present study, we evaluated the prevalence of low-responders to aspirin and the factors affecting platelet aggregability under aspirin therapy in Japanese patients.…”

Section: Editorial P 1077mentioning

confidence: 99%

Characterization of the Antiplatelet Effect of Aspirin at Enrollment and After 2-Year Follow-up in a Real Clinical Setting in Japan

Ikeda

Taniguchi

Watanabe

et al. 2010

Circ J

View full text Add to dashboard Cite

Background:Aspirin is an antiplatelet drug widely used for the prevention of cardiovascular diseases. It has been reported that some patients who exhibit a reduced antiplatelet effect of aspirin have higher cardiovascular risk. It is still controversial whether the antiplatelet effect of aspirin diminishes after a few years of treatment. This study aimed to evaluate the antiplatelet effect of aspirin and its 2-year change in Japanese patients. Methods and Results:Collagen-induced platelet-aggregability was measured at enrollment by conventional optical aggregometer in 239 patients undergoing antiplatelet therapy with aspirin alone. Among them, 167 patients were evaluated after 2 years. Whole blood aggregability based on the screen-filtration method was also evaluated. Optical aggregometer studies showed that 27% of patients were low-responders. Multivariate analyses revealed that female sex and non-use of calcium-channel blockers were associated with low responsiveness. The antiplatelet effect of aspirin did not decrease after 2 years. Similar data were obtained with the whole blood aggregometer. Conclusions:In this Japanese patient group, 27% were low-responders to aspirin, and the antiplatelet effect of aspirin did not decrease after a 2-year interval. (Circ J 2010; 74: 1227 - 1235

show abstract

“…Homozygous 795 T/T displays gene-gene interaction with interleukin-4 receptor α polymorphism (I 50 V) [53]. The C 924 T polymorphism is associated with aspirin resistance [54], bronchial asthma [55], and atopic asthma [56]. Interestingly, the 924 T polymorphism also demonstrates interleukin gene-gene interactions, with an interleukin-5 polymorphism (T 746 C) reducing pulmonary function [56].…”

Section: Htp Genetic Variantsmentioning

confidence: 99%

Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease

Gleim¹,

Kasza²,

Martin³

et al. 2009

Curr Atheroscler Rep

View full text Add to dashboard Cite

Twenty-five years have passed since Vane and colleagues proposed a prostacyclin and thromboxane balance as critical to cardiovascular homeostasis. Prostacyclin prevents platelet aggregation and promotes vasodilatation, opposing the effects of thromboxane. Possible compensation by redundant functions, such as nitric oxide, long prevented appreciation of this balance. Effective use of low-dose aspirin in the secondary prevention of atherothrombosis suggested a clinical importance for the balance. However, it was not until the cyclooxygenase-2 inhibitor rofecoxib was withdrawn because of increased cardiovascular events that this critical balance was confirmed in humans. Moreover, clinical observations are supported by elegant animal receptor knockout experiments and subsequent human genetic variant studies. Combined, these findings provide valuable insight into the roles of these prostanoids in the development of atherothrombosis, emphasizing the need to reevaluate the use of selective prostacyclin- and thromboxane-based therapies in cardiovascular disease.

show abstract

Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity

Cited by 26 publications

References 25 publications

Interaction between ALOX5AP-SG13S114A/T and COX-2-765G/C increases susceptibility to cerebral infarction in a Chinese population

Interaction between ALOX5AP-SG13S114A/T and COX-2-765G/C increases susceptibility to cerebral infarction in a Chinese population

Characterization of the Antiplatelet Effect of Aspirin at Enrollment and After 2-Year Follow-up in a Real Clinical Setting in Japan

Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease

Contact Info

Product

Resources

About